| News

Alentis raises 12.5 million Swiss francs

30.04.2019

The Basel-based biotech company Alentis Therapeutics AG has successfully concluded a CHF 12.5 million Series A financing co-lead by BioMedPartners and BB Pureos Bioventures and joined by BPI France, Schröder Adveq and the HTGF. Alentis develops therapeutics in advanced liver disease and cancer.

Thomas Baumert, Alentis

BaseLaunch, a healthcare accelerator operated by BaselArea.swiss, has been instrumental as an early stage financial and operational supporter in the formation of the company. Very important has also been SATT Conectus – the tech transfer office of all the players in public research in Alsace – by providing building and securing the IP portfolio.

According to a press release, Alentis was founded upon research work conducted by the group of Professor Thomas Baumert, the principal founder of the company. He works at the University of Strasbourg, the Inserm Institute for Viral and Liver Disease, the Laboratory of Excellence HepSYS and the Institut Hospitalo-Universitaire Strasbourg.

Alentis’ lead program is a humanized monoclonal antibody against a target that is fundamental to the pathology of liver fibrosis and hepatocellular carcinoma (HCC). Alentis’ research is powered by its proprietary drug discovery platform, which is based on a prognostic liver disease signature holding promise for further drug candidates in liver disease.

Andreas Wallnöfer, General Partner at BioMedPartners and board member of Alentis, describes Baumert’s research as “truly translational, with the result that a rapid transition from preclinical research to clinical development can be expected.

Alentis is led by Dr. Markus Ewert, who was previously CBO at Ablynx, headed global corporate development at GE Healthcare, and held various leadership positions at Novartis.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Botanikind settles in Basel
Basel Area Business & Innovation, Innovation, Invest

Botanikind settles in Basel

The internationally active Swiss company Botanikind has settled in Basel and established Botanikind AG there. It provides natural ingredients for...

Read More
Kinarus secures capital commitment of 57 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Kinarus secures capital commitment of 57 million Swiss francs

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group...

Read More
Biotech startups from the Basel Area confirm leading position
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Biotech startups from the Basel Area confirm leading position

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also...

Read More
T3 Pharma wins Swiss Economic Award
Basel Area Business & Innovation, Innovation, Invest

T3 Pharma wins Swiss Economic Award

T3 Pharma has won the Swiss Economic Award 2021. Switzerland’s most prestigious young entrepreneur prize is awarded by the Swiss...

Read More
Worg selects Basel Area for European headquarters
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Worg selects Basel Area for European headquarters

Worg Pharmaceuticals has opted to establish its European headquarters at the site Allschwil of the Switzerland Innovation Park Basel Area....

Read More
ten23 health settles in Basel
Basel Area Business & Innovation, Innovation, Invest

ten23 health settles in Basel

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health....

Read More
Lumineo installs translucent concrete wall for Vinci
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Lumineo installs translucent concrete wall for Vinci

The global construction and energy group Vinci engaged the jurassic Lumineo Group to design a wall made from translucent concrete...

Read More
Roivant invests 200 million dollars in Immunovant
Basel Area Business & Innovation, Innovation, Invest

Roivant invests 200 million dollars in Immunovant

The Basel-based Roivant Group has invested a total of 200 million dollars in the US biopharmaceutical company Immunovant. This investment...

Read More
Lyfegen collaborating with Johnson & Johnson
Basel Area Business & Innovation, Innovation, Invest

Lyfegen collaborating with Johnson & Johnson

The Basel-based startup Lyfegen has developed a platform for value-based healthcare. This should provide improved outcomes for patients and result...

Read More
Bottmedical enters the market with innovative braces
Basel Area Business & Innovation, Innovation, Invest

Bottmedical enters the market with innovative braces

The Basel-based startup Bottmedical has developed clear braces made from bio-based polymers. After closing a successful financing round, the company...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.